Dual inhibition of EGFR and mTOR pathways in small cell lung cancer

British Journal of Cancer

Volumn 103, Issue 5, 2010, Pages 622-628

  Schmid, K ^a   Bago Horvath, Z ^a   Berger, W ^b   Haitel, A ^a   Cejka, D ^a   Werzowa, J ^a   Filipits, M ^b   Herberger, B ^b   Hayden, H ^a   Sieghart, W ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

EGFR; erlotinib; mTOR; RAD001; small cell lung cancer; targeted therapy

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ETOPOSIDE; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; S6 KINASE; TOPOTECAN; VINCRISTINE SULFATE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHAGY; CANCER ADJUVANT THERAPY; CELL PROLIFERATION; CELL VIABILITY; DRUG POTENTIATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL SURVIVAL; CELLS, CULTURED; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEIN-SERINE-THREONINE KINASES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SIROLIMUS; SMALL CELL LUNG CARCINOMA; XENOPUS PROTEINS;

EID: 77955980679     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605761     Document Type: Article

References (34)

1. Azzariti A, Porcelli L, Gatti G, Nicolin A, Paradiso A (2008) Synergic antiproliferative and antiangiogenic effects of EGFR and mTor inhibitors on pancreatic cancer cells. Biochem Pharmacol 75: 1035-1044
2. Belyanskaya LL, Hopkins-Donaldson S, Kurtz S, Simões-Wuest AP, Yousefi S, Simon HU, Stahel R, Zangemeister-Wittke U (2005) Cisplatin activates Akt in small cell lung cancer cells and attenuates apoptosis by survivin upregulation. Int J Cancer 117: 755-763
3. Berger W, Spiegl-Kreinecker S, Buchroithner J, Elbling L, Pirker C, Fischer J, Micksche M (2001) Overexpression of the human major vault protein in astrocytic brain tumour cells. Int J Cancer 94: 377-382
4. Bianco R, Garofalo S, Rosa R, Damiano V, Gelardi T, Daniele G, Marciano R, Ciardiello F, Tortora G (2008) Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs. Br J Cancer 98: 923-930
5. Bjornsti MA, Houghton PJ (2004) The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4: 335-348
6. Blackhall FH, Pintilie M, Michael M, Leighl N, Feld R, Tsao MS, Shepherd FA (2003) Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer. Clin Cancer Res 9: 2241-2247
7. Buck E, Eyzaguirre A, Brown E, Petti F, McCormack S, Haley JD, Iwata KK, Gibson NW, Griffin G (2006) Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther 5: 2676-2684
8. Ciardiello F, Tortora G (2008) EGFR antagonists in cancer treatment. N Engl J Med 358: 1160-1174
9. Crazzolara R, Bradstock KF, Bendall LJ (2009) RAD001 (Everolimus) induces autophagy in acute lymphoblastic leukemia. Autophagy 5: 727-728
10. Damstrup L, Rude Voldborg B, Spang-Thomsen M, Bruenner N, Skovgaard Poulsen H (1998) In vitro invasion of small-cell lung cancer cell lines correlates with expression of epidermal growth factor receptor. Br J Cancer 78: 631-640
11. Dornetshuber R, Heffeter P, Kamyar MR, Peterbauer T, Berger W, Lemmens-Gruber R (2007) Enniatin exerts p53-dependent cytostatic and p53-independent cytotoxic activites against human cancer cells. Chem Res Toxicol 20: 465-473
12. Fischer B, Marinov M, Arcaro A (2007) Targeting receptor tyrosine kinase signalling in small cell lung cancer (SLCL): what have we learned so far? Cancer Treat Rev 33: 391-406
13. Herberger B, Berger W, Puhalla H, Schmid K, Novak S, Brandstetter A, Pirker C, Gruenberger T, Filipits M (2009) Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells. Mol Cancer Ther 8: 1547-1556
14. Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C, Eckhardt SG, Tolcher A, Britten CD, Denis L, Ferrante K, vonHoff DD, Silberman S, Rowinsky EK (2001) Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19: 3267-3279
15. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O Toole T, Lustgarten S, Moore L, Motzer RJ; Global ARCC Trial (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356: 2271-2281
16. Iwamaru A, Kondo Y, Iwado E, Aoki H, Fujiwara K, Yokoyama T, Mills GB, Kondo S (2007) Silencing mammalian target of rapamycin signaling by small interfering RNA enhances rapamycin-induced autophagy in malignant glioma cells. Oncogene 26: 1840-1851
17. Jimeno A, Kulesza P, Wheelhouse J, Chan A, Zhang X, Kincaid E, Chen R, Clark DP, Forastiere A, Hidalgo M (2007) Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy. Br J Cancer 96: 952-959
18. Kaseda S, Ueda M, Ozawa S, Ishihara T, Abe O, Shimizu N (1989) Expression of epidermal growth factor receptors in four histologic cell types of lung cancer. J Surg Oncol 42: 16-20
19. Kim KW, Mutter RW, Cao C, Albert JM, Freeman M, Hallahan DE, Lu B (2006) Autophagy for cancer therapy through inhibition of proapoptotic proteins and mammalian target of rapamycin signaling. J Biol Chem 281: 36883-36890
20. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139
21. Moore AM, Einhorn LH, Estes D, Govindan R, Axelson J, Vinson J, Breen TE, Yu M, Hanna NH (2006) Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial. Lung Cancer 52: 93-97
22. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Gruenwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A; RECORD-1 Study Group. (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372: 449-456
23. Nakamura Y, Oka M, Soda H, Shiozawa K, Yoshikawa M, Itoh A, Ikegami Y, Tsurutani J, Nakatomi K, Kitazaki T, Doi S, Yoshida H, Kohno S (2005) Gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. Cancer Res 65: 1541-1546
24. Okamoto I, Araki J, Suto R, Shimada M, Nakagawa K, Fukuoka M (2006) EGFR mutation in gefitinib-responsive small-cell lung cancer. Ann Oncol 17: 1028-1029
25. Ono M, Kuwano M (2006) Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin Cancer Res 12: 7242-7251
26. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J, Rosen N (2006) mTOR inhibition induces upstream receptor kinase signaling and activates Akt. Cancer Res 66: 1500-1508
27. Owonikoko TK, Stoller RG, Petro D, Flaugh R, Hershberger PA, Belani CP, Argiris AE (2008) Phase II study of RAD001 (Everolimus) in previously treated small cell lung cancer. J Clin Oncol Suppl 26: 19017
28. Pandya KJ, Levy DE, Hidalgo M, Cohen RB, Lee MW, Schiller JH, Johnson DH (2005) A randomized, phase II ECOG trial of two dose levels of temsirolimus (CCI-779) in patients with extensive stage small cell lung cancer in remission after induction chemotherapy. J Clin Oncol Suppl 23: 7005
29. Puglisi M, Dolly S, Faria A, Myerson JS, Popat S, O'Brien HE (2010) Treatment options for small cell lung cancer-do we have more choice? British J Cancer 102: 629-638
30. Sieghart W, Fuereder T, Schmid K, Cejka D, Werzowa J, Wrba F, Wang X, Gruber D, Rasoul-Rockenschaub S, Peck-Radosavljevic M, Wacheck V (2007) Mammalian target of rapamycin pathway activity in hepato-cellular carcinomas of patients undergoing liver transplantation. Transplantation 83: 425-432
31. Tanno S, Ohsaki Y, Nakanishi K, Toyoshima E, Kikuchi K (2004) Small cell lung cancer cells express EGFR and tyrosine phosphorylation of EGFR is inhibited by gefitinib ('Iressa', ZD1839). Oncol Rep 12: 1053-1057
32. Wang MY, Lu KV, Zhu S, Dia EQ, Vivanco I, Shackleford GM, Cavenee WK, Mellinghoff IK, Cloughesy TF, Sawyers CL, Mischel PS (2006) Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibition in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res 66: 7864-7869
33. Wu C, Wangpaichitr M, Feun L, Kuo MT, Robles C, Lampidis T, Savaraj N (2005) Overcoming cisplatin resistance by mTOR inhibitor in lung cancer. Mol Cancer 4: 25
34. Zijlstra JG, De Vries EG, Mulder NH (1987) Multifactorial drug resistance in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res 47: 1780-1784